| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 29 | 2024 | 304 | 8.470 |
Why?
|
| Mitral Valve Insufficiency | 13 | 2024 | 192 | 4.730 |
Why?
|
| Endoscopy | 22 | 2024 | 348 | 4.720 |
Why?
|
| Cardiac Surgical Procedures | 24 | 2024 | 475 | 4.570 |
Why?
|
| Coronary Artery Bypass | 23 | 2024 | 234 | 4.400 |
Why?
|
| Heart Valve Prosthesis Implantation | 18 | 2024 | 178 | 3.840 |
Why?
|
| Mitral Valve | 18 | 2024 | 262 | 3.710 |
Why?
|
| Aortic Valve | 17 | 2024 | 243 | 3.320 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 9 | 2024 | 39 | 3.100 |
Why?
|
| Coronary Artery Disease | 15 | 2024 | 362 | 3.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 10 | 2024 | 251 | 2.160 |
Why?
|
| Heart-Assist Devices | 11 | 2019 | 756 | 2.020 |
Why?
|
| Heart Valve Prosthesis | 10 | 2024 | 97 | 1.740 |
Why?
|
| Robotics | 3 | 2022 | 269 | 1.670 |
Why?
|
| Thoracotomy | 4 | 2019 | 64 | 1.660 |
Why?
|
| Aortic Valve Stenosis | 6 | 2024 | 143 | 1.630 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2022 | 64 | 1.620 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2021 | 51 | 1.500 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2023 | 181 | 1.470 |
Why?
|
| Heart Failure | 11 | 2023 | 1180 | 1.460 |
Why?
|
| Aortic Aneurysm, Thoracic | 5 | 2020 | 89 | 1.380 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2020 | 242 | 1.210 |
Why?
|
| Humans | 139 | 2024 | 89073 | 1.180 |
Why?
|
| Heart Rupture | 4 | 2021 | 9 | 1.180 |
Why?
|
| Aged | 63 | 2024 | 19078 | 1.140 |
Why?
|
| Mitral Valve Annuloplasty | 4 | 2020 | 16 | 1.130 |
Why?
|
| Postoperative Complications | 14 | 2020 | 2275 | 1.110 |
Why?
|
| Mammary Arteries | 4 | 2024 | 33 | 1.100 |
Why?
|
| Heart Neoplasms | 8 | 2015 | 63 | 1.100 |
Why?
|
| Aorta, Thoracic | 4 | 2017 | 166 | 1.070 |
Why?
|
| Treatment Outcome | 43 | 2024 | 8203 | 1.070 |
Why?
|
| Reoperation | 8 | 2020 | 598 | 1.060 |
Why?
|
| Male | 88 | 2024 | 42254 | 1.050 |
Why?
|
| Middle Aged | 70 | 2024 | 25865 | 1.000 |
Why?
|
| Obesity, Morbid | 2 | 2018 | 233 | 0.990 |
Why?
|
| Retrospective Studies | 40 | 2024 | 9003 | 0.990 |
Why?
|
| Chordae Tendineae | 3 | 2021 | 23 | 0.980 |
Why?
|
| Coronary Vessels | 3 | 2023 | 190 | 0.940 |
Why?
|
| Cardiopulmonary Bypass | 9 | 2024 | 157 | 0.930 |
Why?
|
| Cerebrovascular Circulation | 4 | 2017 | 227 | 0.900 |
Why?
|
| Operative Time | 8 | 2024 | 142 | 0.900 |
Why?
|
| Sternotomy | 2 | 2023 | 23 | 0.880 |
Why?
|
| Iliac Artery | 3 | 2024 | 38 | 0.870 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2019 | 132 | 0.850 |
Why?
|
| Arterio-Arterial Fistula | 2 | 2019 | 6 | 0.830 |
Why?
|
| Prosthesis Implantation | 3 | 2019 | 126 | 0.790 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2023 | 42 | 0.760 |
Why?
|
| Female | 78 | 2024 | 46014 | 0.760 |
Why?
|
| Pulmonary Artery | 3 | 2023 | 319 | 0.750 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2017 | 20 | 0.740 |
Why?
|
| Optic Disk | 2 | 2017 | 13 | 0.730 |
Why?
|
| Endovascular Procedures | 4 | 2020 | 270 | 0.720 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2019 | 99 | 0.700 |
Why?
|
| Perfusion | 4 | 2019 | 235 | 0.690 |
Why?
|
| Mortality | 2 | 2018 | 149 | 0.690 |
Why?
|
| Marfan Syndrome | 3 | 2016 | 28 | 0.670 |
Why?
|
| Heart Atria | 3 | 2015 | 281 | 0.670 |
Why?
|
| Catheters | 1 | 2019 | 76 | 0.650 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 115 | 0.640 |
Why?
|
| Vascular Patency | 7 | 2023 | 126 | 0.640 |
Why?
|
| Heart Transplantation | 5 | 2021 | 717 | 0.630 |
Why?
|
| Blood Transfusion | 1 | 2019 | 166 | 0.630 |
Why?
|
| Aortic Aneurysm | 3 | 2016 | 80 | 0.620 |
Why?
|
| Regional Blood Flow | 3 | 2017 | 198 | 0.610 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 6777 | 0.600 |
Why?
|
| Hemangioma | 2 | 2015 | 64 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2019 | 2657 | 0.580 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 18 | 0.580 |
Why?
|
| Vertebral Artery | 1 | 2017 | 24 | 0.580 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 98 | 0.570 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2017 | 109 | 0.560 |
Why?
|
| Splenic Rupture | 1 | 2016 | 7 | 0.560 |
Why?
|
| Monitoring, Intraoperative | 1 | 2017 | 110 | 0.550 |
Why?
|
| Myocardial Infarction | 6 | 2023 | 373 | 0.550 |
Why?
|
| Splenectomy | 1 | 2016 | 82 | 0.550 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 149 | 0.540 |
Why?
|
| Tissue Scaffolds | 2 | 2019 | 111 | 0.530 |
Why?
|
| Anemia, Hemolytic | 1 | 2015 | 19 | 0.530 |
Why?
|
| Research Design | 1 | 2019 | 597 | 0.520 |
Why?
|
| Heart Valve Diseases | 5 | 2018 | 115 | 0.510 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 67 | 0.510 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 50 | 0.510 |
Why?
|
| Antithrombin III Deficiency | 1 | 2015 | 3 | 0.510 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2016 | 61 | 0.510 |
Why?
|
| Cardiac Catheterization | 4 | 2016 | 302 | 0.510 |
Why?
|
| Aorta, Abdominal | 1 | 2015 | 59 | 0.500 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2020 | 226 | 0.500 |
Why?
|
| Heart Diseases | 1 | 2017 | 298 | 0.500 |
Why?
|
| Emergencies | 1 | 2015 | 121 | 0.480 |
Why?
|
| Embolization, Therapeutic | 3 | 2016 | 262 | 0.480 |
Why?
|
| Hospital Mortality | 5 | 2020 | 386 | 0.470 |
Why?
|
| Adult | 37 | 2024 | 26508 | 0.450 |
Why?
|
| Coronary Angiography | 5 | 2024 | 242 | 0.450 |
Why?
|
| Length of Stay | 5 | 2019 | 732 | 0.440 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 1 | 0.420 |
Why?
|
| Spinal Curvatures | 1 | 2012 | 7 | 0.420 |
Why?
|
| Postoperative Period | 6 | 2023 | 301 | 0.420 |
Why?
|
| Back Pain | 1 | 2012 | 42 | 0.410 |
Why?
|
| Risk Factors | 10 | 2021 | 5466 | 0.410 |
Why?
|
| Cardioplegic Solutions | 2 | 2023 | 17 | 0.400 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 43 | 0.390 |
Why?
|
| Spinal Fractures | 1 | 2012 | 77 | 0.390 |
Why?
|
| Atrial Fibrillation | 6 | 2023 | 350 | 0.390 |
Why?
|
| Bromides | 2 | 2021 | 7 | 0.390 |
Why?
|
| Hyperhidrosis | 2 | 2021 | 10 | 0.380 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 273 | 0.380 |
Why?
|
| Microcirculation | 4 | 2017 | 104 | 0.330 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2021 | 113 | 0.320 |
Why?
|
| Heart Arrest, Induced | 4 | 2023 | 30 | 0.320 |
Why?
|
| Heart Rupture, Post-Infarction | 2 | 2019 | 7 | 0.310 |
Why?
|
| Thrombosis | 2 | 2022 | 302 | 0.300 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 146 | 0.300 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 3657 | 0.280 |
Why?
|
| Feasibility Studies | 2 | 2019 | 779 | 0.270 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1837 | 0.270 |
Why?
|
| Echocardiography | 7 | 2019 | 937 | 0.270 |
Why?
|
| Liposarcoma | 1 | 2005 | 12 | 0.260 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 21 | 0.250 |
Why?
|
| Heart Ventricles | 2 | 2013 | 779 | 0.250 |
Why?
|
| Vena Cava, Superior | 1 | 2005 | 60 | 0.250 |
Why?
|
| Myocardial Bridging | 1 | 2024 | 5 | 0.240 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2019 | 595 | 0.240 |
Why?
|
| Catheterization | 4 | 2024 | 237 | 0.240 |
Why?
|
| Time Factors | 12 | 2020 | 5320 | 0.240 |
Why?
|
| Lumbar Vertebrae | 6 | 2012 | 151 | 0.240 |
Why?
|
| Bioprosthesis | 1 | 2024 | 39 | 0.240 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 603 | 0.240 |
Why?
|
| Thoracic Wall | 1 | 2024 | 25 | 0.230 |
Why?
|
| Japan | 5 | 2021 | 303 | 0.230 |
Why?
|
| Myocardium | 2 | 2017 | 571 | 0.230 |
Why?
|
| Aneurysm | 2 | 2019 | 60 | 0.220 |
Why?
|
| Cannula | 2 | 2023 | 50 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2020 | 346 | 0.210 |
Why?
|
| Perioperative Period | 2 | 2019 | 25 | 0.210 |
Why?
|
| Arteriovenous Fistula | 2 | 2019 | 53 | 0.210 |
Why?
|
| Prosthesis Design | 3 | 2019 | 296 | 0.210 |
Why?
|
| Stroke | 3 | 2023 | 982 | 0.210 |
Why?
|
| Femoral Artery | 2 | 2024 | 83 | 0.200 |
Why?
|
| Prognosis | 4 | 2019 | 3773 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 182 | 0.200 |
Why?
|
| Device Removal | 3 | 2019 | 167 | 0.190 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 70 | 0.190 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2018 | 61 | 0.180 |
Why?
|
| Hemodynamics | 3 | 2019 | 729 | 0.180 |
Why?
|
| Young Adult | 3 | 2017 | 6289 | 0.180 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2019 | 66 | 0.180 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2019 | 3 | 0.180 |
Why?
|
| Hemorrhage | 2 | 2022 | 278 | 0.180 |
Why?
|
| Splenic Vein | 1 | 2019 | 5 | 0.180 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2018 | 136 | 0.170 |
Why?
|
| Intraoperative Complications | 2 | 2020 | 188 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 21 | 0.170 |
Why?
|
| Diseases in Twins | 2 | 2016 | 65 | 0.170 |
Why?
|
| Sutureless Surgical Procedures | 1 | 2019 | 6 | 0.170 |
Why?
|
| Physician Assistants | 1 | 2019 | 21 | 0.170 |
Why?
|
| Swine | 3 | 2019 | 581 | 0.170 |
Why?
|
| Ligation | 1 | 2019 | 51 | 0.170 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 7 | 0.170 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 66 | 0.170 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 311 | 0.170 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2019 | 41 | 0.170 |
Why?
|
| Hospitals, Low-Volume | 1 | 2019 | 18 | 0.160 |
Why?
|
| Coronary Stenosis | 1 | 2019 | 39 | 0.160 |
Why?
|
| Safety | 1 | 2019 | 149 | 0.160 |
Why?
|
| Thoracic Surgery | 1 | 2019 | 44 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2019 | 140 | 0.160 |
Why?
|
| Retreatment | 1 | 2018 | 108 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 36 | 0.160 |
Why?
|
| Vascular Calcification | 1 | 2019 | 51 | 0.160 |
Why?
|
| Pericardiectomy | 1 | 2017 | 9 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 143 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2019 | 292 | 0.150 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2017 | 10 | 0.150 |
Why?
|
| Myxoma | 3 | 2003 | 30 | 0.150 |
Why?
|
| Gender Identity | 1 | 2018 | 53 | 0.150 |
Why?
|
| Morbidity | 1 | 2018 | 149 | 0.150 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 43 | 0.140 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 12 | 0.140 |
Why?
|
| Ophthalmic Artery | 1 | 2016 | 3 | 0.140 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 85 | 0.140 |
Why?
|
| Ventricular Function, Right | 1 | 2018 | 146 | 0.140 |
Why?
|
| Spinal Fusion | 6 | 1998 | 86 | 0.140 |
Why?
|
| Overweight | 1 | 2017 | 119 | 0.140 |
Why?
|
| Shock, Hemorrhagic | 1 | 2016 | 12 | 0.140 |
Why?
|
| Scoliosis | 4 | 1998 | 32 | 0.140 |
Why?
|
| Thoracic Vertebrae | 3 | 2012 | 51 | 0.140 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2017 | 78 | 0.140 |
Why?
|
| Syndrome | 1 | 2017 | 449 | 0.140 |
Why?
|
| Transplantation, Heterotopic | 1 | 2016 | 46 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 390 | 0.130 |
Why?
|
| Polytetrafluoroethylene | 1 | 2016 | 74 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 197 | 0.130 |
Why?
|
| Surgeons | 1 | 2020 | 247 | 0.130 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 11 | 0.130 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 106 | 0.130 |
Why?
|
| Recurrence | 4 | 2016 | 1140 | 0.130 |
Why?
|
| Lymphopenia | 1 | 2015 | 31 | 0.130 |
Why?
|
| Stents | 2 | 2016 | 395 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 99 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1710 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2016 | 100 | 0.130 |
Why?
|
| Angiography | 1 | 2016 | 208 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 37 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 570 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 237 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 138 | 0.120 |
Why?
|
| Endoleak | 1 | 2015 | 41 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 398 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 116 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 106 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2005 | 109 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 363 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2018 | 771 | 0.120 |
Why?
|
| Tissue Engineering | 1 | 2016 | 185 | 0.120 |
Why?
|
| Palliative Care | 1 | 2016 | 263 | 0.120 |
Why?
|
| Comorbidity | 1 | 2017 | 948 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 741 | 0.110 |
Why?
|
| Vascular Grafting | 1 | 2013 | 16 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2015 | 120 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1855 | 0.110 |
Why?
|
| Biopsy | 1 | 2017 | 1182 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1239 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1706 | 0.100 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2012 | 33 | 0.100 |
Why?
|
| Spondylolisthesis | 3 | 2001 | 12 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 200 | 0.100 |
Why?
|
| Chemokine CCL2 | 2 | 2003 | 47 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2752 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1715 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2005 | 69 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 966 | 0.090 |
Why?
|
| Subclavian Artery | 2 | 2016 | 43 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2017 | 3443 | 0.090 |
Why?
|
| Cyclosporine | 2 | 2003 | 237 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 3147 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2362 | 0.090 |
Why?
|
| Sleep Apnea, Central | 1 | 2009 | 14 | 0.080 |
Why?
|
| Tricuspid Valve | 2 | 2021 | 97 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 364 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2001 | 193 | 0.080 |
Why?
|
| Psoriasis | 2 | 2003 | 245 | 0.080 |
Why?
|
| Adolescent | 8 | 2015 | 9237 | 0.080 |
Why?
|
| Papillary Muscles | 2 | 2017 | 17 | 0.080 |
Why?
|
| Pheochromocytoma | 1 | 2007 | 49 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 2291 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1715 | 0.070 |
Why?
|
| Heart Aneurysm | 1 | 2006 | 22 | 0.070 |
Why?
|
| Coronary Aneurysm | 1 | 2006 | 16 | 0.070 |
Why?
|
| Stroke Volume | 2 | 2020 | 462 | 0.070 |
Why?
|
| Survival Rate | 3 | 2019 | 1889 | 0.070 |
Why?
|
| Anesthesia | 1 | 2007 | 169 | 0.060 |
Why?
|
| Tetralogy of Fallot | 1 | 2005 | 44 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 296 | 0.060 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 60 | 0.060 |
Why?
|
| Chicago | 2 | 2019 | 1423 | 0.060 |
Why?
|
| Spinal Osteophytosis | 2 | 1993 | 3 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 94 | 0.060 |
Why?
|
| Animals | 7 | 2019 | 27324 | 0.060 |
Why?
|
| Bacteremia | 1 | 2004 | 102 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2024 | 60 | 0.060 |
Why?
|
| Spinal Cord Compression | 2 | 1993 | 27 | 0.060 |
Why?
|
| Skin | 2 | 1998 | 581 | 0.060 |
Why?
|
| Equipment Design | 4 | 2018 | 415 | 0.060 |
Why?
|
| Fracture Healing | 1 | 2003 | 36 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2003 | 75 | 0.060 |
Why?
|
| Thymidine Phosphorylase | 1 | 2003 | 5 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 360 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2003 | 98 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 160 | 0.050 |
Why?
|
| Chronic Disease | 4 | 2019 | 948 | 0.050 |
Why?
|
| Cervical Vertebrae | 2 | 1993 | 81 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 16 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 252 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 57 | 0.050 |
Why?
|
| Internal Fixators | 2 | 1992 | 14 | 0.050 |
Why?
|
| Pericardium | 1 | 2002 | 70 | 0.050 |
Why?
|
| Ischemia | 1 | 2024 | 251 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2001 | 38 | 0.050 |
Why?
|
| Cineradiography | 1 | 2001 | 25 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2004 | 269 | 0.050 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2001 | 21 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1755 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2001 | 15 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 161 | 0.050 |
Why?
|
| Acute Disease | 2 | 2020 | 841 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2000 | 25 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1108 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 370 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2003 | 1796 | 0.050 |
Why?
|
| Heart Bypass, Right | 2 | 2000 | 12 | 0.050 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2001 | 41 | 0.050 |
Why?
|
| Axilla | 1 | 2021 | 104 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 1997 | 27 | 0.040 |
Why?
|
| Spine | 2 | 1998 | 102 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 47 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 320 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 55 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 76 | 0.040 |
Why?
|
| Child | 6 | 2023 | 7149 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2001 | 210 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2020 | 82 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2019 | 19 | 0.040 |
Why?
|
| Inservice Training | 1 | 2019 | 38 | 0.040 |
Why?
|
| Movement | 1 | 2001 | 307 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 370 | 0.040 |
Why?
|
| Sclerotherapy | 1 | 1999 | 16 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 261 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1999 | 34 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 185 | 0.040 |
Why?
|
| Halothane | 1 | 1998 | 12 | 0.040 |
Why?
|
| Hemodilution | 1 | 1998 | 13 | 0.040 |
Why?
|
| Carbon Radioisotopes | 1 | 1998 | 35 | 0.040 |
Why?
|
| Movement Disorders | 1 | 1998 | 44 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1998 | 45 | 0.040 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1998 | 17 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 1998 | 36 | 0.040 |
Why?
|
| Anesthesia, Inhalation | 1 | 1998 | 36 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 125 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 1998 | 16 | 0.040 |
Why?
|
| Interactive Ventilatory Support | 1 | 2018 | 5 | 0.040 |
Why?
|
| Fluorine Radioisotopes | 1 | 1998 | 25 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 102 | 0.040 |
Why?
|
| Methionine | 1 | 1998 | 65 | 0.040 |
Why?
|
| Thoracic Arteries | 1 | 1998 | 6 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 1999 | 73 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 1998 | 83 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 1998 | 28 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1998 | 126 | 0.040 |
Why?
|
| Isoflurane | 1 | 1998 | 64 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 1998 | 30 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 975 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 216 | 0.040 |
Why?
|
| Anesthetics, Inhalation | 1 | 1998 | 98 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 98 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1998 | 142 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 192 | 0.040 |
Why?
|
| Calcinosis | 1 | 2019 | 230 | 0.040 |
Why?
|
| Rheumatic Heart Disease | 1 | 1997 | 30 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 1998 | 124 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 1998 | 279 | 0.040 |
Why?
|
| Intervertebral Disc Displacement | 2 | 1993 | 22 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 426 | 0.030 |
Why?
|
| Balloon Occlusion | 1 | 2016 | 29 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 1591 | 0.030 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1996 | 18 | 0.030 |
Why?
|
| Dermatomyositis | 1 | 1996 | 18 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 971 | 0.030 |
Why?
|
| Graft Survival | 1 | 2019 | 898 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 848 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 850 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 645 | 0.030 |
Why?
|
| Rituximab | 1 | 2015 | 119 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 988 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 385 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 264 | 0.030 |
Why?
|
| Aortography | 1 | 2015 | 65 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 202 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 780 | 0.030 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 1994 | 8 | 0.030 |
Why?
|
| Low Back Pain | 1 | 1994 | 41 | 0.030 |
Why?
|
| Ribonucleases | 1 | 1994 | 93 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1994 | 145 | 0.030 |
Why?
|
| Spinal Nerve Roots | 1 | 1993 | 17 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 1363 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1994 | 445 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 682 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 4273 | 0.030 |
Why?
|
| Bone Screws | 1 | 1992 | 45 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 576 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2002 | 67 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1990 | 32 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 887 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 2552 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1990 | 283 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 894 | 0.020 |
Why?
|
| Range of Motion, Articular | 2 | 2001 | 154 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 1996 | 763 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2009 | 113 | 0.020 |
Why?
|
| Polysomnography | 1 | 2009 | 151 | 0.020 |
Why?
|
| Pneumonia | 1 | 1990 | 182 | 0.020 |
Why?
|
| Radiography | 3 | 1997 | 809 | 0.020 |
Why?
|
| Pregnancy | 2 | 2005 | 3010 | 0.020 |
Why?
|
| Incidence | 3 | 1998 | 1592 | 0.020 |
Why?
|
| Dogs | 2 | 1998 | 704 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1987 | 64 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 216 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6957 | 0.020 |
Why?
|
| Avian Leukosis | 1 | 1985 | 1 | 0.020 |
Why?
|
| Braces | 2 | 1998 | 13 | 0.020 |
Why?
|
| Biomechanical Phenomena | 2 | 2001 | 473 | 0.020 |
Why?
|
| Fetal Death | 1 | 2005 | 57 | 0.020 |
Why?
|
| Hypothermia | 1 | 2005 | 26 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 2005 | 20 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 70 | 0.020 |
Why?
|
| Heart Rate | 2 | 1998 | 493 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2005 | 140 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2003 | 5 | 0.010 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2003 | 12 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1985 | 309 | 0.010 |
Why?
|
| Lac Operon | 1 | 2003 | 47 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 253 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 177 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 31 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1998 | 3717 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 2003 | 34 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 313 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2002 | 19 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2003 | 94 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 200 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2003 | 61 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 293 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2003 | 168 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 2002 | 49 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 493 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 276 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 349 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2003 | 269 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 446 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 217 | 0.010 |
Why?
|
| Survival Analysis | 2 | 1999 | 1533 | 0.010 |
Why?
|
| Vincristine | 1 | 2001 | 112 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2001 | 94 | 0.010 |
Why?
|
| Prednisone | 1 | 2001 | 258 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 299 | 0.010 |
Why?
|
| Joint Instability | 1 | 2001 | 82 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2001 | 298 | 0.010 |
Why?
|
| Macaca | 1 | 2000 | 89 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 56 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 46 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 299 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 711 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 2327 | 0.010 |
Why?
|
| Macrophages | 1 | 2003 | 571 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 306 | 0.010 |
Why?
|
| Time | 1 | 1999 | 76 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 1310 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2000 | 524 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1940 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2476 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 3027 | 0.010 |
Why?
|
| Hematocrit | 1 | 1998 | 68 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1998 | 31 | 0.010 |
Why?
|
| Kyphosis | 1 | 1998 | 14 | 0.010 |
Why?
|
| Vasodilation | 1 | 1998 | 93 | 0.010 |
Why?
|
| Mediastinum | 1 | 1998 | 47 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1998 | 43 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 1998 | 81 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 1998 | 40 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1998 | 126 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 260 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1998 | 33 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1998 | 57 | 0.010 |
Why?
|
| Cineangiography | 1 | 1997 | 13 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1998 | 61 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2000 | 421 | 0.010 |
Why?
|
| Leg | 1 | 1998 | 140 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 2011 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1997 | 156 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1997 | 103 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1997 | 198 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1997 | 225 | 0.010 |
Why?
|
| Rotation | 1 | 1997 | 91 | 0.010 |
Why?
|
| Remission Induction | 1 | 1999 | 740 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1998 | 260 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 590 | 0.010 |
Why?
|
| Observer Variation | 1 | 1997 | 610 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 2001 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1997 | 202 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1997 | 684 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 1996 | 108 | 0.010 |
Why?
|
| Eosinophil Granule Proteins | 1 | 1994 | 20 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1994 | 44 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1998 | 899 | 0.010 |
Why?
|
| Sciatica | 1 | 1993 | 4 | 0.010 |
Why?
|
| Pentetic Acid | 1 | 1993 | 25 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 2014 | 0.010 |
Why?
|
| Gadolinium | 1 | 1993 | 103 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1996 | 281 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1993 | 134 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1993 | 264 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1998 | 705 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1992 | 253 | 0.010 |
Why?
|
| Colony-Stimulating Factors | 1 | 1990 | 14 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1990 | 166 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 11742 | 0.010 |
Why?
|
| Age Factors | 1 | 1994 | 1867 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1990 | 1012 | 0.000 |
Why?
|
| Contrast Media | 1 | 1993 | 1090 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 3000 | 0.000 |
Why?
|
| Muscles | 1 | 1987 | 193 | 0.000 |
Why?
|
| Avian Leukosis Virus | 1 | 1985 | 4 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1985 | 87 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1985 | 230 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1985 | 145 | 0.000 |
Why?
|
| Chickens | 1 | 1985 | 212 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1985 | 374 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 2347 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1985 | 755 | 0.000 |
Why?
|